Company Overview and News
KUALA LUMPUR (Oct 15): The FBM KLCI pared some of its gains at midday break, as regional markets remained jittery with U.S.President Donald Trump threatening to impose another round of tariffs on China.
HLFBF 5183 PECGF 1082 7113 5681 TPGVF 7006 5168 5014 9334 6033 5199 TGLVY 5238 4588 PNADF MYPRY HIPEF PNAGF HRGHY
KUALA LUMPUR (Oct 15): The FBM KLCI rose 0.24% at mid-morning today, defending its level above the 1,730-point level, lifted by gains at select blue chips.
HLFBF 7293 BRDBF MLYNF 7113 TPGVF 2089 5199 5210 3026 2836 HIPEF GEBHF HRGHY 5183 MLYBY PECGF UPBMF 1082 5681 5168 TGLVY 5436 5238 1155 0047
IPG Mediabrands has announced that BPN, the media agency under the IPG Mediabrands network, has been awarded global media duties for AirAsia Bhd and AirAsia X Bhd following a competitive pitch process that spanned 23 markets.
AirAsia X Bhd (Oct 11, 24.5 sen) Downgrade to neutral with a lower target price (TP) of 26 sen: Losses could widen in the third quarter of financial year 2018 (3QFY18). Recall that AirAsia X Bhd’s (AAX) net profit slumped into the red in the first half of FY18, as a result of elevated fuel cost. On average, fuel price came in +33.7% year-on-year higher from US$54.6 per barrel since December 2017. Largely, this was attributable to the anticipated US sanctions on Iranian oil exports, shale bottlenecks and Venezuelan turmoil.
Aviation Sector Maintain neutral: The key thrust of Transport Minister Anthony Loke’s address at the “Malaysia: A New Dawn” conference on Tuesday, was that the country’s interests will be best served with airports and airlines working together to enable more flights and draw more tourists. Hence, airports need to expand, and airlines should be given the full support needed to grow.
5238 MYPRY 5014
PETALING JAYA: Intensifying competition and cost pressure have turned the near-term outlook of the Malaysian aviation sector more challenging, following a disappointing earnings performance in the second quarter of financial year of 2018 (2Q18).
5238 MYPRY 5014
KUALA LUMPUR (Oct 2): Brent crude oil prices rose to a near four-year high today as markets adjust to the prospect of tighter supply once US sanctions against Iran kick in next month.
5238 C6L SINGY SINGF
KUALA LUMPUR: When the RM10 billion Kuala Lumpur International Airport (KLIA) in Sepang opened its doors to the public in June 1998, the underlying goal was to turn it into a regional aviation hub to the likes of Changi Airport in Singapore and Don Mueang International Airport in Bangkok, Thailand.
5238 MYPRY 5014
KUALA LUMPUR: Passengers will pay more to fly Malaysia Airlines as the national carrier has reinstated a fuel surcharge on its ticket price from Sept 18, 2018 as oil prices continue to rise.
5238 MLYAF C6L CPCAY 0293 CPCAF SINGY SINGF
IN January, Khazanah Nasional Bhd said Malaysia Airlines Bhd had until the middle of next year to be profitable. But there are signs that the airline could miss yet another deadline.
WHEN sovereign wealth fund Khazanah Nasional Bhd unveiled a turnaround plan for the country’s flagship carrier in August 2014 that saw the rebooting of Malaysian Airline System Bhd (MAS) into a leaner Malaysia Airlines Bhd, there were high hopes it would achieve success similar to that at Japan Airlines (JAL).
AL 5238 MLYAF JAPSY C6L ALLLZ BOE MYPRY SINGY BA 5014 SINGF
KUALA LUMPUR (Sept 19): The FBM KLCI rose 0.53% at mid-morning today and climbed above the 1,800-point level, tracking gains at the regional markets.
HLFBF PBLOF 1082 7113 5681 TPGVF 1295 5168 3794 6033 TGLVY 5238 4588 PNADF 1201 0026 5819 PNAGF HRGHY
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...